Johnson & Johnson: Pulmonary Disease, Chronic Obstructive trials

The registry lists 10 Pulmonary Disease, Chronic Obstructive studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 1 have results posted.

Early Phase 1 1Phase 1 2Phase 2 4Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT01437878Phase 2Results posted
• A Study of Smoking Cessation Patterns in Participants Undergoing Lung SurgeryCompletedNCT04313361
• A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPDCompletedNCT02140346Phase 1
• Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD PatientsCompletedNCT01970618Phase 1
• A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01966549Phase 2
• An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01867762Phase 2
• A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01475292Phase 2
• A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary DiseaseCompletedNCT01274507Early Phase 1
• A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT00380796
• A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPDCompletedNCT00056264Phase 3